The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLms Capital Regulatory News (LMS)

Share Price Information for Lms Capital (LMS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.10
Bid: 18.10
Ask: 19.00
Change: -0.35 (-1.90%)
Spread: 0.90 (4.972%)
Open: 18.10
High: 18.10
Low: 18.10
Prev. Close: 18.45
LMS Live PriceLast checked at -
LMS Capital is an Investment Trust

To achieve absolute total returns over the medium to longer term, principally through capital gains and supplemented with the generation of a longer term income yield, by investing primarily in private equity.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Third Quarter 2022 Update

28 Oct 2022 07:00

RNS Number : 4183E
LMS Capital PLC
28 October 2022
 

 

 

 

 

 

 

 

 

 

 

28 October 2021

 

LMS CAPITAL PLC

Third Quarter 2022 Update

 

 

LMS Capital plc (the "Company") the listed Investment Company, provides the following update covering the period from 30 June 2022 to date.

 

Financial Highlights

 

· Unaudited Net Asset Value ("NAV") at 30 September 2022 was £48.8 million (60.5p per share). This compares to £47.0 million (58.2 p per share) at 30 June 2022, an increase in the quarter of 4.5% after adjusting for dividends paid;

· Interim dividend of £0.2 million (0.3p per share) paid in September 2022; and

· Cash at 30 September 2022 was £18.4 million (22.8p per share) compared to £18.9 million (23.5p per share) at 30 June 2022.

 

The portfolio overall has benefitted from unrealised foreign exchange gains in the quarter with a small net increase in underlying valuations.

 

As we enter a period of further economic uncertainty our significant cash balances put us in a strong position to evaluate and make the most of opportunities in our chosen sectors.

 

Unaudited Net Asset Value at 30 September 2022

 

After adjusting for dividends paid in the quarter of £0.2 million, the net increase in NAV during the quarter was £2.0 million, comprising the following:

· Unrealised foreign exchange ("FX") gains of £2.1 million on the investment portfolio. The US dollar strengthened by approximately 8.3% against sterling during the quarter. Approximately 75% of the Company's investments are US dollar denominated;

· Underlying gains and accrued income on the investment portfolio were £0.4 million;

· Non portfolio foreign exchange gains of £0.2 million, running costs of £0.4 million, and investment related costs of £0.1 million.

 

The 30 September 2022 NAV is summarised below:

 

Unaudited 

30 September 2022 

 

Unaudited

30 June 2022

£ 000s

Quoted Investments

197

182

Unquoted Investments

17,501

16,093

Funds

15,204

13,970

Subtotal Investment portfolio

32,902

30,245

Cash

18,377

18,932

Other Net Assets/Liabilities 

(2,440)

(2,216)

Net Asset Value

48,839

46,961

 

 

The NAV at the end of September is based on the valuation of the Company's investments as at 30 June 2022, adjusted for transactions in the three months ended 30 September 2022, price movements on quoted securities, movements in foreign currency exchange rates, cash calls and distributions from funds, and the latest information available from third party fund managers.

 

Portfolio Net Gains

 

The portfolio net unrealised gains during the quarter to 30 September were £2.5 million, of which £2.1 million were unrealised foreign exchange gains and £0.4 million were net unrealised gains in underlying investment valuations. The movements, are summarised below:

 

Quoted Investments - £0.2 million (30 June 2022 - £0.2 million)

 

The Company's quoted investment valuation has not changed materially since the 30 June 2022. The principal investment is a small holding in IDE Group Limited.

 

Unquoted Investments - £17.5 million (30 June 2022 - £16.1 million)

 

The Company's unquoted investments showed unrealised FX gains of £1.4 million and an unrealised loss in the underlying investment valuations of £0.2 million.

 

The principal holdings are Dacian Petroleum, Medhost, Elateral and ICU, managed by San Francisco Equity Partners.

 

Investment

Currency

30 Sept. 2022

£' million

30 June 2022

£' million

Dacian Petroleum

USD

Onshore oil and gas production assets in Romania

10.6

9.4

Medhost

USD

Provides cloud based enterprise and departmental management and healthcare engagement solutions to community hospitals in the US.

5.8

5.3

Elateral

Sterling

UK/US software company in the digital marketing sector providing marketing content management solutions

0.6

0.6

ICU

USD

Design and distribution of eyewear, principally reading glasses, through large US retailers

0.3

0.6

Other investments

USD/

Sterling

0.2

0.2

Total

 

 

17.5

16.1

 

Dacian - The increase in valuation since the half year comprises unrealised FX gains of £0.9 million and accrued loan interest of £0.3 million. The acquired portfolio of onshore oil and gas wells has now been operated by the Dacian team for 10 months. As reported at the half year, a build up of backlog maintenance prior to Dacian's ownership has required remediation and has diverted the team from some of its planned workover activity during the year. The team is gradually managing the reactive maintenance needs and has conducted some workover projects achieving an increase in production since commencing operations in November 2021. The business is EBITDA positive and cash generative and has benefitted from strong energy prices during the year.

 

Medhost - The increase in valuation of £0.5 million arises from unrealised FX gains, the underlying investment valuation is unchanged from the half year. The company operates in a mature market and continues to be profitable and cash generative and performing in line with budget.

 

Elateral - The valuation is unchanged from half year. During the quarter Elateral received some additional working capital finance from investors, of which LMS' share was £0.2 million.

 

ICU (managed by San Francisco Equity Partners) - The reduction of £0.3 million during the quarter principally comprises a reduction in the underlying valuation reflecting concerns around progress with an exit process that has been underway for several months. Greater clarity around the outcome is anticipated by the year end.

 

Funds - £15.2 million (30 June 2022 - £14.0 million)

 

The Company's fund investments showed unrealised foreign exchange gains of £0.7 million and a gain in the underlying asset valuations of £0.6 million.

 

The Company's fund investments include its holding in Brockton Capital Fund I, Opus Capital Partners, Weber Capital Partners ("Weber") and five other smaller fund interests.

 

Investment

Currency

30 Sept. 2022

£' million

30 June 2022

£' million

Brockton Capital Fund 1

Sterling

UK real estate fund, the remaining asset of which is a debt investment in a high end London residential development

6.4

6.0

Opus Venture Capital Fund 2

USD

Early-stage technology fund with two principal remaining assets

5.8

5.4

Weber Capital Partners

USD

US listed microcap investment fund focussed primarily on medical and technology sectors

2.3

1.8

Other investments

USD/

Sterling

0.7

0.8

Total

 

 

15.2

14.0

 

Brockton - The increase in valuation since the half year comprises the third quarter movement in the discounted cash flow valuation of this asset.

 

Opus - The increased valuation comprises unrealised FX gains of £0.5 million less a reduction of £0.1 million in the underlying valuation by the third party manager. The reduction in the underlying valuation reflects movement in the general market benchmark values used by the manager for valuation purposes.

 

Weber - The increased valuation since the half year comprises unrealised FX gains of £0.2 million and gains in the underlying market value of the portfolio of £0.3 million. Notwithstanding general market conditions this fund benefitted during the quarter from a significant increase in market value of one of its holdings.

 

The carrying value of the funds is based on the latest available information from the respective fund managers, generally the 30 June 2022 fund valuation reports except for Weber, which is based on a 30 September 2022 valuation.

 

Portfolio Realisations

 

There were no portfolio realisations or fund distributions during the third quarter.

 

The information contained in this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon publication of this announcement, this inside information is now considered to be in the public domain.

 

For further information please contact:

LMS Capital PLC - Nick Friedlos, Managing Director

0207 935 3555

 

Shore Capital - Robert Finlay

0207 408 4050

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
QRTMRBTTMTJTTTT
Date   Source Headline
25th Apr 20244:09 pmRNSInvestor Presentation
25th Apr 20243:10 pmRNSHolding(s) in Company
24th Apr 20244:42 pmRNSNotice of AGM
19th Mar 20247:00 amRNS2023 Final Results
8th Mar 20242:23 pmRNSHolding(s) in Company
23rd Feb 20247:00 amRNSNet Asset Value(s)
29th Jan 20247:00 amRNSPortfolio Update - Brockton Fund 1
27th Dec 20237:00 amRNSPortfolio Update
21st Dec 20237:00 amRNSRetirement living investment platform
30th Oct 20237:00 amRNSThird Quarter 2023 Update
16th Aug 20233:11 pmRNSLong Term Incentive Plan Awards
1st Aug 20237:00 amRNSHalf year results for the 6 months ended 30.06.23
23rd May 20234:03 pmRNSDividend Declaration - REPLACEMENT
18th May 20234:08 pmRNSDividend Declaration
18th May 20234:03 pmRNSResult of AGM
5th May 20237:00 amRNSStatement re Notice to shareholders
28th Apr 20237:00 amRNSFirst Quarter 2023 Update
24th Apr 20232:42 pmRNSNotice of AGM
24th Apr 20232:37 pmRNSNotice of AGM
14th Apr 202310:47 amRNSHolding(s) in Company
22nd Mar 20233:04 pmRNSHolding(s) in Company
20th Mar 20237:00 amRNSFinal Results fo rthe Year Ended 31 December 2022
7th Feb 20237:00 amRNSNet Asset Value(s)
25th Nov 20223:54 pmRNSHolding(s) in Company
28th Oct 20227:00 amRNSThird Quarter 2022 Update
2nd Aug 20227:09 amRNSHalf year Report and Dividend declaration
19th May 20223:42 pmRNSDividend Declaration
18th May 20224:27 pmRNSResult of AGM
27th Apr 20227:00 amRNSFirst Quarter 2022 Update
22nd Apr 20227:00 amRNSNotice of Annual General Meeting 2022
10th Mar 20227:00 amRNSFinal Results for the Year Ended 31 December 2021
31st Jan 20227:00 amRNSNAV Estimate as at 31 December 2021
15th Dec 20214:41 pmRNSSecond Price Monitoring Extn
15th Dec 20214:36 pmRNSPrice Monitoring Extension
23rd Nov 20217:00 amRNSPortfolio Update
12th Nov 202112:34 pmRNSPortfolio Update
22nd Oct 20217:00 amRNSThird Quarter 2021 Update
23rd Sep 202112:16 pmRNSHolding(s) in Company
4th Aug 20217:00 amRNSDividend Declaration
3rd Aug 20217:00 amRNSHalf-year Report
8th Jul 202110:16 amRNSChange of Registered Office
18th May 20214:36 pmRNSPrice Monitoring Extension
13th May 20213:32 pmRNSFinal Dividend for the year ended 31 December 2020
12th May 20214:20 pmRNSResult of AGM
29th Apr 20217:00 amRNSFirst Quarter 2021 Update
9th Apr 20217:00 amRNSAnnual Financial Report
31st Mar 20214:41 pmRNSSecond Price Monitoring Extn
31st Mar 20214:35 pmRNSPrice Monitoring Extension
12th Mar 20217:09 amRNSFinal Results for the Year Ended 31 December 2020
2nd Mar 20214:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.